{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:11:05Z","timestamp":1767150665210,"version":"build-2238731810"},"reference-count":27,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.vaccine.2022.03.066","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T07:20:02Z","timestamp":1649056802000},"page":"2856-2868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein"],"prefix":"10.1016","volume":"40","author":[{"given":"Mohammad Hassan","family":"Pouriayevali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Teimoori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saber","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asghar","family":"Abdoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delaram","family":"Doroud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Salehi-Vaziri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Shahali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Kadkhodazadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talieh","family":"Sabouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Ali","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Panahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fereidoon","family":"Khoshroo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anahita","family":"Bahmanjeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yury","family":"Valdes-Balbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Garcia-Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Verez-Bencomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Biglari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazem","family":"Baesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.vaccine.2022.03.066_b0005","doi-asserted-by":"crossref","first-page":"8834","DOI":"10.1128\/JVI.00752-06","article-title":"Crimean-Congo hemorrhagic fever virus genomics and global diversity","volume":"80","author":"Deyde","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.03.066_b0010","doi-asserted-by":"crossref","first-page":"102123","DOI":"10.1016\/j.frl.2021.102123","article-title":"Optimal lockdown policy for vaccination during COVID-19 pandemic","volume":"45","author":"Fu","year":"2022","journal-title":"Finance Res Lett"},{"key":"10.1016\/j.vaccine.2022.03.066_b0015","article-title":"COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations","volume":"12","author":"He","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.vaccine.2022.03.066_b0020","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(21)00103-X","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial","volume":"8","author":"Frater","year":"2021","journal-title":"Lancet HIV"},{"issue":"10275","key":"10.1016\/j.vaccine.2022.03.066_b0025","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.vaccine.2022.03.066_b0030","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.2021.3199","article-title":"SARS-CoV-2 vaccines","volume":"325","author":"Creech","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2022.03.066_b0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/v13010109","article-title":"Domains and functions of spike protein in sars-cov-2 in the context of vaccine design","volume":"13","author":"Xia","year":"2021","journal-title":"Viruses"},{"issue":"13","key":"10.1016\/j.vaccine.2022.03.066_b0040","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00647-20","article-title":"The nucleocapsid protein of SARS\u2013CoV-2: a target for vaccine development","volume":"94","author":"Dutta","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.03.066_b0045","doi-asserted-by":"crossref","unstructured":"Abdoli A, Aalizadeh R, Aminianfar H, Kianmehr Z, Teimoori A, Azimi E, et al. Safety and potency of BIV1\u2010CovIran inactivated vaccine candidate for SARS\u2010CoV\u20102: a preclinical study. Wiley Online Library; 2021.","DOI":"10.1101\/2021.06.10.447951"},{"issue":"8","key":"10.1016\/j.vaccine.2022.03.066_b0050","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3758\/BF03194551","article-title":"On the analysis of psychometric functions: the Spearman-K\u00e4rber method","volume":"63","author":"Miller","year":"2001","journal-title":"Perception Psychophys."},{"key":"10.1016\/j.vaccine.2022.03.066_b0055","article-title":"A single dose of SARS CoV 2 FINLAY FR 1A dimeric RBD recombinant vaccine enhances neutralization response in COVID19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial","author":"Chang-Monteagudo","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2022.03.066_b0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.coviro.2021.03.009","article-title":"Animal models for SARS-CoV-2","volume":"48","author":"Lee","year":"2021","journal-title":"Curr Opin Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.03.066_b0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2022.03.066_b0070","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"7843","key":"10.1016\/j.vaccine.2022.03.066_b0075","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-020-2943-z","article-title":"COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice","volume":"589","author":"Zheng","year":"2021","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.vaccine.2022.03.066_b0080","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1080\/21645515.2017.1419108","article-title":"Development of novel vaccine vectors: Chimpanzee adenoviral vectors","volume":"14","author":"Guo","year":"2018","journal-title":"Hum Vaccines Immunother."},{"issue":"1","key":"10.1016\/j.vaccine.2022.03.066_b0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-00221-3","article-title":"Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19","volume":"5","author":"Graham","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2022.03.066_b0090","article-title":"Ad26. COV2. S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing","author":"van der Lubbe","year":"2021","journal-title":"bioRxiv"},{"issue":"11","key":"10.1016\/j.vaccine.2022.03.066_b0095","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41591-020-1070-6","article-title":"Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters","volume":"26","author":"Tostanoski","year":"2020","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.vaccine.2022.03.066_b0100","doi-asserted-by":"crossref","first-page":"109664","DOI":"10.1016\/j.celrep.2021.109664","article-title":"Combining spike-and nucleocapsid-based vaccines improves distal control of SARS-CoV-2","volume":"36","author":"Dangi","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2022.03.066_b0105","article-title":"Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity","author":"Matchett","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2022.03.066_b0110","doi-asserted-by":"crossref","unstructured":"Gabitzsch E, Safrit JT, Verma M, Rice A, Sieling P, Zakin L, et al. Complete protection of nasal and lung airways against SARS-CoV-2 challenge by antibody plus Th1 dominant N-and S-specific T-cell responses to subcutaneous prime and thermally-stable oral boost bivalent hAd5 vaccination in an NHP study. bioRxiv. 2021:2020.12. 08.416297.","DOI":"10.1101\/2020.12.08.416297"},{"issue":"7","key":"10.1016\/j.vaccine.2022.03.066_b0115","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2022.03.066_b0120","doi-asserted-by":"crossref","first-page":"236","DOI":"10.7883\/yoken.JJID.2004.236","article-title":"Defense mechanisms against influenza virus infection in the respiratory tract mucosa","volume":"57","author":"Tamura","year":"2004","journal-title":"JPN J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.03.066_b0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11262-006-0064-x","article-title":"Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1\/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy\u2014a review","volume":"33","author":"Becker","year":"2006","journal-title":"Virus Genes"},{"key":"10.1016\/j.vaccine.2022.03.066_b0130","doi-asserted-by":"crossref","unstructured":"de Vrij EL, Vogelaar PC, Goris M, Houwertjes MC, Herwig A, Dugbartey GJ, et al. Platelet dynamics during natural and pharmacologically induced torpor and forced hypothermia. PLoS One 2014;9:e93218.","DOI":"10.1371\/journal.pone.0093218"},{"key":"10.1016\/j.vaccine.2022.03.066_b0135","doi-asserted-by":"crossref","unstructured":"van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, et al. Publisher correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques (Nature,(2020), 586, 7830,(578-582), 10.1038\/s41586-020-2608-y). Nature 2021;590.","DOI":"10.1038\/s41586-020-2608-y"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2022.10.019","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22003851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22003851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T11:02:01Z","timestamp":1726916521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22003851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":27,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0264410X22003851"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.066","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}